RLAY vs. RXRX

Last updated Apr 2, 2026

Compare and contrast key facts about Relay Therapeutics, Inc. (RLAY) and Recursion Pharmaceuticals, Inc. (RXRX).

Performance

RLAY vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Relay Therapeutics, Inc. (RLAY) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

RLAY vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
RLAY Relay Therapeutics, Inc.	27.30%	105.34%	-62.58%	-26.31%	-51.35%	-5.80%
RXRX Recursion Pharmaceuticals, Inc.	-25.18%	-39.50%	-31.44%	27.89%	-54.99%	-45.27%

Fundamentals

Market Cap RLAY : $1.85B RXRX : $1.61B
EPS RLAY : -$1.61 RXRX : -$1.39
PS Ratio RLAY : 120.46 RXRX : 19.03
PB Ratio RLAY : 3.26 RXRX : 1.43
Total Revenue (TTM) RLAY : $15.36M RXRX : $74.56M
Gross Profit (TTM) RLAY : $0.00 RXRX : $3.73M
EBITDA (TTM) RLAY : -$302.74M RXRX : -$579.69M

Returns By Period

In the year-to-date period, RLAY achieves a 27.30% return, which is significantly higher than RXRX's -25.18% return.

RLAY

• 1D: 8.24%
• 1M: 10.01%
• YTD: 27.30%
• 6M: 102.44%
• 1Y: 336.03%
• 3Y*: -13.20%
• 5Y*: -21.53%
• 10Y*: —

RXRX

• 1D: -0.33%
• 1M: -15.70%
• YTD: -25.18%
• 6M: -40.00%
• 1Y: -39.94%
• 3Y*: -22.87%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RLAY vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RLAY

RLAY Risk / Return Rank: 98
RLAY Sharpe Ratio Rank: 99
RLAY Sortino Ratio Rank: 98
RLAY Omega Ratio Rank: 95
RLAY Calmar Ratio Rank: 99
RLAY Martin Ratio Rank: 99

RXRX

RXRX Risk / Return Rank: 18
RXRX Sharpe Ratio Rank: 19
RXRX Sortino Ratio Rank: 22
RXRX Omega Ratio Rank: 23
RXRX Calmar Ratio Rank: 15
RXRX Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RLAY vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Relay Therapeutics, Inc. (RLAY) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RLAY	RXRX	Difference
Sharpe ratio Return per unit of total volatility	4.74	-0.48	+5.22
Sortino ratio Return per unit of downside risk	4.35	-0.32	+4.67
Omega ratio Gain probability vs. loss probability	1.51	0.97	+0.55
Calmar ratio Return relative to maximum drawdown	15.81	-0.72	+16.53
Martin ratio Return relative to average drawdown	41.06	-1.43	+42.49
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RLAY vs. RXRX - Sharpe Ratio Comparison

The current RLAY Sharpe Ratio is 4.74, which is higher than the RXRX Sharpe Ratio of -0.48. The chart below compares the historical Sharpe Ratios of RLAY and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RLAY	RXRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	4.74	-0.48	+5.22
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.28	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.24	-0.40	+0.16

Correlation

The correlation between RLAY and RXRX is 0.50, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

RLAY vs. RXRX - Dividend Comparison

Neither RLAY nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RLAY vs. RXRX - Drawdown Comparison

The maximum RLAY drawdown since its inception was -96.75%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for RLAY and RXRX.

Drawdown Indicators

	RLAY	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	-96.75%	-93.13%	-3.62%
Max Drawdown (1Y) Largest decline over 1 year	-19.68%	-58.17%	+38.49%
Max Drawdown (5Y) Largest decline over 5 years	-94.76%	—	—
Current Drawdown Current decline from peak	-82.50%	-92.60%	+10.10%
Average Drawdown Average peak-to-trough decline	-68.90%	-74.78%	+5.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.58%	29.48%	-21.90%

Volatility

RLAY vs. RXRX - Volatility Comparison

Relay Therapeutics, Inc. (RLAY) has a higher volatility of 17.27% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 14.66%. This indicates that RLAY's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RLAY	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.27%	14.66%	+2.61%
Volatility (6M) Calculated over the trailing 6-month period	48.72%	54.53%	-5.81%
Volatility (1Y) Calculated over the trailing 1-year period	71.73%	83.97%	-12.24%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	77.48%	94.52%	-17.04%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.75%	94.52%	-16.77%

Financials